Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data.

BMJ

Department of Clinical Pharmacology and Toxicology, Canberra Hospital, PO Box 11, Woden, ACT 2606, Australia.

Published: December 2002

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC137809PMC
http://dx.doi.org/10.1136/bmj.325.7376.1332DOI Listing

Publication Analysis

Top Keywords

fatal toxicity
4
toxicity serotoninergic
4
serotoninergic antidepressant
4
antidepressant drugs
4
drugs analysis
4
analysis united
4
united kingdom
4
kingdom mortality
4
mortality data
4
fatal
1

Similar Publications

Background: Anthrax is a life-threatening zoonotic disease caused by Gram-positive, spore-forming bacterium . It manifests as a cutaneous, gastrointestinal, and respiratory disease. The cutaneous form ranges from a self-limiting lesion to severe edematous lesions with toxemic shock.

View Article and Find Full Text PDF

is a Gram-positive bacterium, also known as Group A (GAS), that has become a significant threat to the healthcare system, infecting more than 18 million people and resulting in more than 500,000 deaths annually worldwide. GAS infection rates decreased gradually during the 20th century in Western countries, largely due to improved living conditions and access to antibiotics. However, post-COVID-19, the situation has led to a steep increase in GAS infection rates in Europe, the United States, Australia, and New Zealand, which triggers a global concern.

View Article and Find Full Text PDF

are ubiquitous algae and occasional pathogens of humans and animals. While rare, the infection is often fatal and treatment options are limited to antifungals with low efficiency. Here, using growth curve assays, we demonstrate that five pathogenic species of () were fully inhibited by 50-100 μg/mL of herbicide glyphosate, suggesting novel pathways that can be considered for anti-algal drug development.

View Article and Find Full Text PDF

In recent years, new anticancer drugs have been investigated and approved for the treatment of breast cancer based on improved survival outcomes. However, these new treatments have specific class-related side effects. Pulmonary toxicity has been identified as an adverse event of special interest with everolimus, and is becoming an increasingly significant clinical challenge with the recent approval of trastuzumab deruxtecan.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!